Munich, Germany / Montreal, Canada – 12 January 2022 – TVM Life Science (“TVM”),
a leading International Life Sciences Venture Capital firm, today announces the formal
promotion of Dr. Sascha Berger and Dr. Alain Thibault to General Partner.
Sascha has joined the TVM Capital Life Science team in 2016 as Principal and was
promoted to Partner in 2020. Sascha has more than 15 years professional experience.
He started his career as a management consultant at the Boston Consulting Group and later PricewaterhouseCoopers. He brings extensive experience in deal-making, life sciences venture capital, technology assessment and investment management with an academic background in chemistry and finance.
Alain joined the firm in 2020. He is a medical oncologist and an expert in first-in-man phase of oncology drug development. Prior to joining TVM, he held senior positions at Roche, Janssen, Regeneron and arGEN-X. His area of expertise includes chemotherapy, small molecule targeted therapy and biologics (monoclonal antibodies). His regulatory experience ranges from IND/IMPD-CTA write-up to IND/BLA submission and approval.
Dr. Hubert Birner, Managing Partner at TVM Capital Life Science commented, “Sascha will continue to play a pivotal role in sourcing and managing new investment opportunities for the firm, both for early stage and late-stage opportunities. Sascha already built a strong network into the transatlantic biotech and investor community. We are very pleased to announce Sascha’s promotion to General Partner today.”
Dr. Luc Marengere, Managing Partner at TVM Capital Life Science added, “Alain is a highly respected and accomplished medical oncologist with a strong track record in late pre-clinical/early clinical development in oncology where TVM is currently focusing our early-stage Project Focused Company investment strategy in partnership with Eli Lilly & Company. We are delighted to promote Alain to General Partner.”
Stefan Fischer, Managing Partner (Finance) at TVM Capital Life Science stated, “We wish both new partners continued success as they assume their new leadership responsibilities. This is based on their proven achievements, their strong expertise as well as their commitment to the values of our firm. They reflect the broad spectrum of our talent and know-how along the investment value chain and the valuable contribution to TVM’s portfolio.”
About TVM Capital Life Science
TVM Capital Life Science provides venture capital to international biopharmaceutical, medical technology, and diagnostic companies in North America and the EU. TVM follows a two-pronged strategy with a focus on early-stage and late-stage investments.
For more information please contact:
Managing Partner (Finance), TVM Capital Life Science
+49 89 998 992 36